BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candida...
April 24 2020 - 2:30PM
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”) today announced that it will be hosting an investor
briefing to provide an update on the progress of its subsidiary
ViralClear Pharmaceuticals, Inc, and recent developments of
merimepodib (MMPD).
The Company recently submitted an Investigational New Drug (IND)
Application to the Food and Drug Administration (FDA) to commence a
Phase II clinical trial with merimepodib as a treatment for
COVID-19. The conference call is being held on Wednesday, April 29,
2020 at 11:00 AM ET.
Kenneth L. Londoner, MBA, Chairman and CEO of BioSig
Technologies, Inc. will be joined by Nick Spring, CEO of ViralClear
Pharmaceuticals, Inc., Steven King, COO of ViralClear
Pharmaceuticals, Inc., and Jerome Zeldis, M.D., Ph.D., Executive
Chairman of ViralClear Pharmaceuticals, Inc.
Conference Call Details: Date:
Wednesday, April 29, 2020 Time: 11:00 AM Eastern
Time (ET) Dial in Number for U.S. Callers:
1-877-407-4177 Dial in Number for International
Callers: 1-201-689-8325Participant Entry
Passcode: 13702950 (followed by #)
A replay will be available for two weeks starting on April 29,
2020 at approximately 2:00 PM ET. To access the replay, please dial
1-877-660-6853 in the U.S. and 1-201-612-7415 for international
callers. The conference ID# is 13702950.
On April 24, 2020 the Company announced that ViralClear
submitted an Investigational New Drug (IND) Application to the Food
and Drug Administration (FDA) to commence a Phase II clinical trial
with merimepodib as a treatment for COVID-19. On April 23, 2019,
ViralClear published comparative in vitro data on merimepodib and
remdesivir activity against the COVID-19 novel coronavirus in F1000
Research. Merimepodib was shown to decrease viral production of
COVID-19 coronavirus more than remdesivir at clinically meaningful
drug concentrations in pre-clinical testing.
Upon approval from the FDA to commence, the Phase II clinical
trial will be conducted at Mayo Clinic under the leadership of
Andrew D. Badley, M.D., Professor and Chair of Department of
Molecular Medicine and the Enterprise Chair of COVID-19 Task Force.
The study will be a randomized, placebo-controlled trial to
evaluate the efficacy and safety of Merimepodib in patients with
COVID-19. The placebo-controlled Phase II clinical trial calls for
20 planned patients from three Mayo Clinic sites: Rochester, MN;
Scottsdale, AZ; and Jacksonville, FL. Data from the Phase II trial
is expected within three months of the commencement of the
trial.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClearBioSig’s subsidiary ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
to treat advanced COVID-19. Merimepodib is a broad-spectrum
anti-viral agent that has demonstrated strong activity against the
COVID-19 virus in cell cultures in laboratory testing. ViralClear
plans to initiate a multi-center, phase 2, randomized,
double-blind, placebo-controlled study of the efficacy and safety
of merimepodib administered orally every eight hours for 10 days in
adult patients with advanced COVID-19 upon FDA clearance to
proceed. Merimepodib has been studied in twelve clinical trials
prior to this study, including five trials in patients with
hepatitis C (one phase 1b, one phase 2, two phase 2a, and one phase
2b), one trial in patients with psoriasis (phase 2), and six trials
in healthy volunteers (all phase 1).
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024